Korean J Ophthalmol.  2017 Aug;31(4):368-369. 10.3341/kjo.2017.0018.

Acute Bilateral Anterior Uveitis after a Single Intravenous Infusion of Zoledronic Acid in Metastatic Breast Cancer

• Jun JH

• KMID: 2385588
• DOI: http://doi.org/10.3341/kjo.2017.0018

Abstract

No abstract available.

MeSH Terms

Breast Neoplasms*
Breast*
Infusions, Intravenous*
Uveitis, Anterior*

Figure

• 

  Fig. 1 Ocular findings of anterior acute uveitis after administration of intravenous zoledronic acid (A) and (B) slit-lamp photographs show severe bilateral vascular engorgement of the bulbar conjunctiva. (C) Moderate cellular reaction (grade 3+) of the anterior chamber was seen in the left eye (asterisk). (D) Color fundus photography shows no abnormal finding. (E) Optical coherence tomography shows no macular edema in the right (upper) or left (lower) eye. (F) Posterior synechiae occurred in the left eye after 3 days despite frequent steroid and non-steroidal anti-inflammatory drug eye drop instillations (arrows). (G) After 10 days of treatment, injections of both bulbar conjunctiva subsided after using topical medications. (H) Synechiae were resolved after the use of atropine eye drops.

Reference

1. Patel DV, Horne A, House M, et al. The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology. 2013; 120:773–776. PMID: 23290982.

2. Peterson JD, Bedrossian EH Jr. Bisphosphonate-associated orbital inf lammation: a case report and review. Orbit. 2012; 31:119–123. PMID: 22489855.

3. Sauty A, Pecherstorfer M, Zimmer-Roth I, et al. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone. 1996; 18:133–139. PMID: 8833207.

4. Belliveau MJ, Almeida DR, Urton TE. Acute anterior uveitis following zoledronic acid infusion for osteoporosis. Can J Ophthalmol. 2012; 47:e22–e23. PMID: 23036555.

5. Patel DV, Bolland M, Nisa Z, et al. Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial. Osteoporos Int. 2015; 26:499–503. PMID: 25187119.